ஒன்றுபட்டது மாநிலங்களில் தேசிய நிறுவனங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Malaria parasite. Photo: SENSISEEDSTwo United States (U.S.) Phase 1 clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedented high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites. According to the study published, yesterday, in the journal Nature, by A. Mwakingwe-Omari et al and titled ‘Two chemo-attenuated PfSPZ malaria vaccines induce sterile hepatic immunity’, the vaccine combines live parasites with either of two widely used antimalarial drugs- an approach termed chemoprophylaxis vaccination. x The researchers said a Phase 2 clinical trial of the vaccine is now underway in Mali, a malaria-endemic country. If the approach proves successful there, chemoprophylaxis vaccination, or CVac, potentially could help reverse the stalled decline of global malaria. Currently, there is no vaccine in widespread use for the mosquito-transmitted disease.

United statesPatricke duffyStephenl hoffmanClinical centre in bethesdaUnited states national institutes of healthNational institute of allergySanaria incUnited states national institutesClinical centreInfectious diseasesSouth americanஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது மாநிலங்களில் தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம்தேசிய நிறுவனம் ஆஃப் ஒவ்வாமைஒன்றுபட்டது மாநிலங்களில் தேசிய நிறுவனங்கள்மருத்துவ மையம்